Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative
about
Alzheimer's therapeutics: translation of preclinical science to clinical drug developmentCombotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseShift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventionsα7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumMild cognitive impairment and dementia: the importance of modifiable risk factorsPersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsThe Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inceptionThe advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting.Severity of memory impairment in the elderly: Association with health care resource use and functional limitations in the United StatesSmoking and increased Alzheimer's disease risk: a review of potential mechanismsThe Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementiasLong-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Cholinergic Degeneration and Alterations in the TrkA and p75NTR Balance as a Result of Pro-NGF Injection into Aged Rats.Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.Cognitive improvement of compound danshen in an Aβ25-35 peptide-induced rat model of Alzheimer's disease.Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification.Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease.The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden.Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease.Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disordersPredicting episodic memory performance using different biomarkers: results from Argentina-Alzheimer's Disease Neuroimaging Initiative.Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.The role of cognitive activity in cognition protection: from Bedside to Bench.Use of memantine for the treatment of dementia.Recruitment methods for United States Alzheimer disease prevention trials.Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease.Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders.Benefits and risks of add-on therapies for Alzheimer's disease.
P2860
Q26829267-81E67C3F-6221-42CA-B6EF-34A55A3AE1D1Q26829899-F4E81F6A-D5FF-49F3-B5CA-AE0FE38EA15AQ26830740-6557C139-FC58-4797-9D6E-BC12D4FE9935Q26852967-E3714DCE-A7CF-4852-8657-3F892388E5B7Q26994975-6CCB8FD3-6E8E-49DB-B402-F7313485E9B0Q26997299-EC9B465C-F354-461F-A15A-882EE107E694Q27006831-2BEB42FB-8545-4689-8D20-71B23EE3DC29Q28485924-4BC0DDF0-36CE-4758-8156-C57AA1F9B2A6Q30871982-7356C625-EAB7-4C26-97A0-124B834C5EA2Q30971403-2A95425D-D9D7-40DE-B68B-4D0368D50CE1Q33596862-A357DA21-B8BE-422F-ADA6-9C2E21151455Q33626983-BFCDAA96-B1CC-4FE0-AB15-FFAF53F7FB93Q33902721-600534E6-E0BE-47CE-B13D-DF41F9ED03D3Q34065449-58CEDCE9-4D46-479C-8353-F7273DACBE39Q34301111-938F944F-1289-4339-B63F-3F18A77085CDQ34528182-8F688466-5245-4F35-AAC8-4FC660B8F110Q35006354-C2A681E6-450D-45E6-BD7A-F098326ABE1DQ35117411-DC5ECE51-0612-4270-8D4C-E69220E2EEB8Q35765716-8E3B507E-74CD-4C4A-AE66-8B20D51C7CDDQ35819807-5495D383-1D90-4A03-86E2-6734A6E7BE46Q35930947-28626E79-8E2A-427F-A4C6-E03301C5F5A0Q35972117-BA356520-5770-4A3E-98EF-8EC1B4DB219BQ36121819-1641CF79-A41B-484D-9FCD-CBE00ACA5D3DQ36574825-50398FFE-D39F-44C2-A34F-7ED5C584A5DAQ36588166-9AD9540E-3473-4656-875D-782300DE1069Q36987635-5FDA2734-2622-41BA-83F5-C79CFF8F7A8BQ37262741-1C935C99-0274-4346-9138-3A643D1A4B55Q37265898-9E45D9DE-5607-4AFE-BD61-1784839A3EB4Q37675866-AE5DB76C-418C-4145-A653-D89A7F4E0B0FQ37690649-3A2AB4C8-4995-45DB-BAD2-2205F5714B67Q37726908-C62B80E3-9FA5-4DAD-B2EF-D5C720D87102Q37939987-793CBE8D-9225-48E7-9DE2-BC07DDCBE8CBQ38002365-BB1EE53C-E251-42EB-A932-327BAD89D482Q38066972-3C72BEA3-D77B-4ACA-8CEA-CA6114E494FEQ38106483-9AB5D7A2-51F0-4001-933A-8ACF0A18E4B8Q38164141-8D188D6D-8B61-48F2-A98C-86093FDA4A8CQ38178373-0D2844EC-E17C-43C3-944F-257FFCB1022FQ38391086-A1D94895-1EA5-4C3C-86AE-A8146E968AA5Q38413816-60B3CD2C-3297-4B19-906C-F223E8D4FAC6Q38620338-0553658E-3453-4EB4-BC53-1D3173B1F1C5
P2860
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Treatment with cholinesterase ...... isease Neuroimaging Initiative
@ast
Treatment with cholinesterase ...... isease Neuroimaging Initiative
@en
type
label
Treatment with cholinesterase ...... isease Neuroimaging Initiative
@ast
Treatment with cholinesterase ...... isease Neuroimaging Initiative
@en
prefLabel
Treatment with cholinesterase ...... isease Neuroimaging Initiative
@ast
Treatment with cholinesterase ...... isease Neuroimaging Initiative
@en
P2860
P1433
P1476
Treatment with cholinesterase ...... isease Neuroimaging Initiative
@en
P2093
Lon S Schneider
Philip S Insel
P2860
P356
10.1001/ARCHNEUROL.2010.343
P577
2011-01-01T00:00:00Z